New hives drug put to the test in everyday life
NCT ID NCT07358780
Summary
This study is observing how well a new oral drug called remibrutinib works for adults with chronic spontaneous urticaria (CSU), a condition causing long-lasting hives. It will follow about 500 people in the US for two years to see how effectively the drug controls their symptoms and how safe it is in real-world use, outside of a controlled clinical trial. The goal is to gather practical information to help doctors and patients manage this condition better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Cleaver Dermatology
RECRUITINGKirksville, Missouri, 63501, United States
Conditions
Explore the condition pages connected to this study.